WellSky® and uMed Launch Partnership to Expand Patient Access to National Clinical Research Registries

New initiative enables patients to participate in national research registries from home, with no disruption to care

OVERLAND PARK, Kan.--(BUSINESS WIRE)--WellSky and uMed today announced a strategic partnership that expands patient access to national clinical research registries—longitudinal programs that track real-world patient outcomes and experience—by enabling home care patients to participate in clinical studies from their home. By combining the WellSky network of more than 10,000 home-based care organizations with uMed’s automated registry platform, the collaboration creates a scalable model for collecting high-quality real-world clinical information from patients—particularly underserved, rural, and aging populations—who want to participate in clinical research, with no disruption to their routine or care.

Pairing the WellSky provider network and the uMed ACCESS Cohorts platform, the partnership will enable patients to join national research registries remotely. These registries are designed to collect real-world evidence on patient experiences, treatment preferences, and medication usability across a range of therapeutic areas, including Parkinson’s disease, cardiometabolic conditions, and autoimmune disorders.

“Access to participate in clinical research has historically been limited for many patients, particularly those not connected to major academic medical centers,” said Bill Miller, chairman and CEO of WellSky. “By integrating WellSky’s expansive provider network with uMed’s turnkey registry infrastructure, we are establishing a new framework for inclusive, patient-centered research that meets individuals where they are.”

Through this partnership, providers can enhance the quality of their reporting and measure their performance against national benchmarks. This enables organizations to clearly identify their strengths and opportunities for growth, ultimately leading to improved patient outcomes. The result is a comprehensive model that simultaneously advances scientific understanding, strengthens business practices, and elevates the standard of care.

“uMed’s mission is to make research more accessible and representative,” said Matt Wilson, MD, founder and CEO of uMed. “Partnering with WellSky allows us to reach patients where they are—at home—while ensuring the process is seamless for clinical teams. Together, we’re expanding the potential of real-world evidence generation at scale from patient populations that have historically been out of reach.”

This partnership underscores WellSky’s commitment to improving outcomes, accelerating clinical innovation, and advancing health equity by connecting patients to life-changing research opportunities through their already established provider relationships. The initiative will begin with cardiometabolic and Parkinson’s cohorts in 2026, with plans to expand into additional therapeutic areas.

For additional information about WellSky and our work across the care continuum, visit wellsky.com.

About WellSky^®

WellSky is one of America’s largest and most innovative healthcare technology companies leading the movement for intelligent, coordinated care. Our proven software, analytics, and services power better outcomes and lower costs for stakeholders across the health and community care continuum. In today’s value-based care environment, WellSky helps providers, payers, health systems, and community organizations scale processes, improve collaboration for growth, harness the power of data analytics, and achieve better outcomes by further connecting clinical and social care. WellSky serves more than 20,000 client sites — including the largest hospital systems, blood banks, cell therapy labs, home health and hospice franchises, post-acute providers, government agencies, and human services organizations. Informed by more than 40 years of providing software and expertise, WellSky anticipates clients’ needs and innovates relentlessly to build healthy, thriving communities. For more information, visit wellsky.com.

About uMed

uMed is a real-world evidence and patient cohort company that makes clinical research participation easier and more representative. Through its ACCESS Cohorts platform, uMed builds national, longitudinal registries by linking electronic health records with scalable patient-reported outcomes, generating high-quality real-world data across various conditions. uMed partners with health systems, life-science companies, and care providers to accelerate research, improve understanding of patient journeys, and support evidence generation for regulators, payers, and clinical decision-making. Originally founded in the U.K. and headquartered in Boston. https://umed.io/